Wire · opportunities
FDA committee votes to make peptides more widely available
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 July 2026 · Fusion42 review
An FDA advisory committee voted narrowly to recommend allowing specialized compounding pharmacies to formulate and sell seven specific peptides (BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon) directly to consumers, moving them from a high-risk list to the 503A Bulks List despite FDA scientists' warnings about insufficient safety and efficacy data.
This Wire brief sits within Fusion42's coverage of Digital Health, and 9 sources have reported it between 23 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
If you make peptide manufacturing equipment, quality assurance software, or cold chain logistics, you're about to see demand spike from hundreds of compounding pharmacies trying to enter a market they've been locked out of. The committee just opened a door the FDA wanted sealed—and those pharmacies will need to buy their way to compliance fast.
◆ Coverage
9 sources · first reported 23 Jul 2026 · latest 28 Jul 2026
◆ Related on Wire
◆ Topics